MDxHealth to supply ConfirmMDx testing for veterans
IRVINE, Calif. & HERSTAL, Belgium—February saw MDxHealth SA receiving a U.S. Government Services Administration supply contract to use ConfirmMDx for Prostate Cancer in the Department of Veterans Affairs (VA). The contract, which began Feb. 1, will run five years and will provide coverage of ConfirmMDx testing at the Medicare rate for veterans in the VA Health System. The VA reports that prostate cancer is the most frequently diagnosed cancer among veterans, with approximately 12,000 new cases annually and more than 200,000 prostate biopsies performed in the VA healthcare system each year.
“MDxHealth is proud to support the Department of Veterans Affairs with ConfirmMDx testing to help improve patient management and decision-making on the need for prostate biopsies,” said Dr. Jan Groen, CEO of MDxHealth. “This contract further underscores ConfirmMDx’s clinical value for prostate cancer risk assessment and will be a significant new driver of test volume.”